219 related articles for article (PubMed ID: 20660203)
1. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.
Kim EY; Bhattacharya T; Kunstman K; Swantek P; Koning FA; Malim MH; Wolinsky SM
J Virol; 2010 Oct; 84(19):10402-5. PubMed ID: 20660203
[TBL] [Abstract][Full Text] [Related]
2. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
3. An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.
Widera M; Erkelenz S; Hillebrand F; Krikoni A; Widera D; Kaisers W; Deenen R; Gombert M; Dellen R; Pfeiffer T; Kaltschmidt B; Münk C; Bosch V; Köhrer K; Schaal H
J Virol; 2013 Mar; 87(5):2707-20. PubMed ID: 23255806
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
5. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
6. Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.
Hernandez MM; Fahrny A; Jayaprakash A; Gers-Huber G; Dillon-White M; Audigé A; Mulder LCF; Sachidanandam R; Speck RF; Simon V
J Virol; 2020 Feb; 94(5):. PubMed ID: 31801862
[TBL] [Abstract][Full Text] [Related]
7. APOBEC-mediated editing of viral RNA.
Bishop KN; Holmes RK; Sheehy AM; Malim MH
Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element.
Nowarski R; Prabhu P; Kenig E; Smith Y; Britan-Rosich E; Kotler M
J Mol Biol; 2014 Jul; 426(15):2840-53. PubMed ID: 24859335
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
10. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA.
Russell RA; Moore MD; Hu WS; Pathak VK
Retrovirology; 2009 Feb; 6():16. PubMed ID: 19216784
[TBL] [Abstract][Full Text] [Related]
12. Dissecting APOBEC3G substrate specificity by nucleoside analog interference.
Rausch JW; Chelico L; Goodman MF; Le Grice SF
J Biol Chem; 2009 Mar; 284(11):7047-58. PubMed ID: 19136562
[TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
14. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
15. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G.
Ejima T; Hirota M; Mizukami T; Otsuka M; Fujita M
Int J Mol Med; 2011 Oct; 28(4):613-6. PubMed ID: 21725586
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
17. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
18. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
Hu C; Saenz DT; Fadel HJ; Walker W; Peretz M; Poeschla EM
J Virol; 2010 Nov; 84(22):11981-93. PubMed ID: 20844042
[TBL] [Abstract][Full Text] [Related]
19. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]